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Abstract
Purpose—To estimate atrial fibrillation (AF)–associated costs for stroke hospitalizations among 
Medicare beneficiaries aged ≥65 years in a 11-state region called stroke belt in the United States.
Methods—Using the 2010 Medicare Provider Analysis and Review File database, we analyzed 
costs of stroke hospitalizations conditional on presence of AF (n=226 289) after excluding those 
with subarachnoid hemorrhage, no information on race, or a length of stay [LOS] of 30 or more 
days. We employed regression analysis to estimate for defined subgroups the impact of AF on 
costs while controlling for major potential confounders.
Results—The average cost of all stroke hospitalizations was $27 915. The presence of AF 
increased this cost by $2711 (9.4%; P<0.001). AF-associated costs were $3159, $2610, and $2197 
for patients aged 65–74, 75–84, and ≥85 years, respectively (all P<0.001). Among hospitalization 
with a length of stay (LOS) of 14–29 days, AF increased the costs by $5888 (P<0.001). AF was 
not associated with higher costs for hospitalizations involving intracerebral hemorrhage.
Conclusions—The costs of stroke hospitalizations are high, and they are even higher if the 
patient has AF. Further information is needed on the costs in patients with AF who are taking 
anticoagulants.
Introduction
Atrial fibrillation (AF) increases the risk of stroke, is associated with increased stroke 
severity, and is the main cause of stroke in elderly participants who receive Medicare.1,2 
Medical costs for AF and stroke have been estimated separately,3–5 but there is little 
information on the costs associated with AF among stroke patients. While AF is relatively 
rare in the general population, it is much more common among patients hospitalized for 
stroke because of its powerful role as a risk factor. As such, AF-specific costs among the 
stroke population could play a substantial role influencing the overall costs of stroke care. 
Such costs would be critical for evaluating the cost-effectiveness of stroke interventions, 
especially those involving patients with AF, and thus we investigated hospitalization costs 
associated with AF for stroke patients in an elderly population.
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We used data from the 2010 Medicare Provider Analysis and Review File, which contains 
information on inpatient stays of current Medicare beneficiaries (aged ≥65 years), to identify 
all hospitalizations with a primary or secondary diagnosis of stroke (International 
Classification of Diseases, Ninth Revision [ICD-9] codes 431, 433, 434, 436, 437, 438, 
excluding subarachnoid hemorrhagic stroke) for patients residing in an 11-state region (the 
Stroke Belt) in the U.S. We also excluded hospitalizations that did not have information on 
race or that had a length of stay (LOS) of 30 or more days.
Among the stroke hospitalizations, we searched the data for AF including atrial flutter 
(ICD-9 427.31 and 427.32). The costs were total charges, including the charges for all 
services provided to the beneficiary for the stay regardless of Medicare coverage.
Statistical Analysis
We specified a multivariate regression model for the cost analysis. We ran the regression 
model for the total sample and subgroups formed by age, sex, race, LOS categories, initial 
admission (yes, no) and stroke diagnosis (primary, non-primary) status, and stroke type 
(intracerebral hemorrhage [ICH]; yes, no). We used the Charlson Comorbidity Index to 
control for health status.
We employed mixed-effects models to derive our estimates; these models incorporated 
repeated-measure approaches to account for the effects of possible multiple admissions for 
individual patients during the year. Statistical analyses were performed using SAS version 
9.1.6
Results
We identified 226 289 stroke hospitalizations, with 42 557 (19.1%) having a diagnosis of 
AF (or atrial flutter) (Table 1). The proportion of hospitalizations having AF increased with 
age from 12.4% for those aged 65–74 years to 26.0% for those aged 85 or older. The 
proportions of AF among hospitalizations for women and white patients were higher than 
for their comparison groups. In contrast, the proportions were similar for initial admissions 
and readmissions, (18.8% for both). Overall, mean per-admission costs were $27 915 ($28 
843 for AF admissions and $27 700 for admissions without AF).
After controlling for many potential confounders, AF increased the cost of hospitalization by 
$2711 (9.4%; P<0.001) (Table 2). Age was inversely associated with per-admission cost. AF 
increased the costs by $3159, $2610, and $2197 for patients aged 65–74, 75–84, and ≥85 
years, respectively. Compared with women, men had a higher per-admission cost but a 
lower AF-associated cost ($2481 versus $2865). LOS was significantly and positively 
associated with per-admission costs, while for costs associated with AF increased with LOS 
up to $5888 for hospitalizations with an LOS of 14–29 days.
Initial hospitalizations cost $12 354 more than readmission, and AF increased the cost by 
$2844 for initial hospitalizations and $1735 for readmissions. Admissions in which the 
stroke was primary had a lower per-admission cost than those in which it was not primary, 
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but the AF-associated cost was higher for primary than non-primary strokes. Per admission, 
intracerebral hemorrhage (ICH) cost $10 101 more than non-ICH, but the cost associated 
with AF was higher for non-ICH strokes ($2757) (AF did not significantly increase the cost 
for ICH stroke).
Discussion
Our study may be the one of the first describing the impact of AF on hospitalization costs 
among stroke patients using a large dataset. We found that AF increased the cost of stroke 
hospitalizations after controlling for health status and other potential confounders. This 
finding confirms the fact that stroke with AF is more severe than stroke without this 
disorder.2
Our findings that younger patients had both higher costs per stay and higher AF-associated 
costs than older patients and that men had a higher cost per hospitalization but that women 
had higher AF-associated costs should be useful for developing stroke prevention programs 
that incorporate the prevention or management of AF. Improved prevention of AF in 
younger patients and women might produce cost savings, although that would have to be 
formally tested. Our finding that AF-associated costs were higher for hospitalizations with 
longer LOS invites efforts to improve AF management for stroke patients with longer LOS 
while also perhaps achieving economic efficiencies.
The finding that both per-admission costs and AF-associated costs were higher for initial 
admissions than readmissions was a bit surprising, especially as an earlier investigation 
found that recurrent strokes had poorer outcomes on average than first strokes.7 We also 
found that primary stroke cost less than non-primary stroke but had higher AF-associated 
costs. ICH had much higher costs than non-ICH stroke, but AF-associated costs for ICH 
patients did not differ significantly from those for such patients without AF, while such costs 
for non-ICH strokes were significantly greater. These findings suggest that evaluations of 
the cost-effectiveness of stroke programs should consider stroke admission type (initial or 
readmission), diagnosis status (primary, not primary), and event type (ICH or no-ICH) 
among AF patients.
Our study had several limitations including: 1) As with all studies that rely on medical 
records, the issue of coding error must be considered. Although misdiagnosis issues have 
been investigated in the literature, how this issue would affect the costs in our study is 
unknown. 2) Our study sample consisted entirely of Medicare beneficiaries, and thus the 
cost might be influenced by the Medicare reimbursement rate. 3) We did not incorporate the 
impact of anticoagulant therapy and in-hospital mortality in the cost analysis. Regardless of 
these limitations, however, the fact that we used a large sample and analyzed the costs from 
different angles suggests that our findings should have great utility and wide applicability.
Conclusions
This study indicated that the high costs of stroke hospitalizations can be expected to vary by 
demographic variables, admission status, LOS, and stroke type. Furthermore, we found that 
AF increases costs for a wide variety of patients. The detailed cost information on stroke 
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patients presented here could be used in the development of cost-effective programs for 
stroke prevention, especially among AF patients. Further information is needed on the costs 
in patients with AF who are taking anticoagulants.
References
1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the 
Framingham Study. Stroke. 1991; 22:983–988. [PubMed: 1866765] 
2. Lin HJ, Wolf PA, Kelly-Hayes M, Beiser AS, Kase CS, Benjamin EJ, et al. Stroke severity in atrial 
fibrillation. The Framingham Study. Stroke. 1996; 27:1760–1764. [PubMed: 8841325] 
3. Luengo-Fernandez R, Gray AM, Rothwell PM. Costs of stroke using patient-level data: a critical 
review of the literature. Stroke. 2009; 40:e18–e23. [PubMed: 19109540] 
4. Brinjikji W, Rabinstein AA, Cloft HJ. Hospitalization costs for acute ischemic stroke patients 
treated with intravenous thrombolysis in the United States are substantially higher than Medicare 
payments. Stroke. 2012; 43:1131–1133. [PubMed: 22198978] 
5. Kim MH, Johnston SS, Chu BC, Dalal MR, Schulman KL. Estimation of total incremental health 
care costs in patients with atrial fibrillation in the United States. Cirs Cardiovasc Qual Outcomes. 
2011; 24:313–320.
6. SAS Institute Inc. SAS/STAT User’s Guide, version 9.1. Cary, NC: SAS Institute; 2007. 
7. Samsa GP, Bian J, Lipscomb J, Matchar DB. Epidemiology of recurrent cerebral infarction: a 
Medicare claims-based comparison of first and recurrent strokes on 2-year survival and cost. Stroke. 
1999; 30:338–349. [PubMed: 9933269] 
Wang et al. Page 4

























Wang et al. Page 5
Table 1
Patient Characteristics of Stroke Hospitalizations by Atrial Fibrillation Status, 2010 Medicare Provider 
Analysis and Review File Data
Characteristic Total N (%) or Sample Statistics (n=226 289)
Hospitalizations with AF 
(n=42 557)
Hospitalizations without AF 
(n=183 372)
Age (years)
65–74 77 993 (34.5) 9656 (12.4) 68 337 (87.6)
75–84 90 326 (39.9) 17 829 (19.7) 72 497 (80.3)
85 or older 57 970 (25.6) 15 072 (26.0) 42 898 (74.0)
Sex
Male 98 117 (43.4) 17 323 (17.7) 80 794 (82.3)
Female 128 172 (56.6) 25 234 (19.7) 102 938 (80.3)
Race
White 178 453 (78.9) 3829 (20.6) 141 624 (79.4)
Black 45 097 (19.9) 5260 (11.7) 39 837 (88.3)
Others 2739 (1.2) 468 (17.1) 2271 (82.9)
Average length of stay in days (SE) 7.05 (0.01) 6.93 (0.03) 7.08 (0.02)
Initial Admission
Yes 157 441 (69.6) 29 628 (18.8) 127 813 (81.2)
No 68 848 (30.4) 12 929 (18.8) 55 919 (81.2)
Stroke as a Primary Diagnosis
Yes 84 970 (37.5) 17 448 (20.5) 67 522 (79.5)
No 141 319 (62.5) 25 109 (17.8) 116210 (82.2)
Intracerebral Hemorrhage (ICH)
Yes 8465 (3.7) 1827 (21.6) 6638 (78.4)
No 217 824 (96.3) 40 730 (18.7) 177 094 (81.3)
Mean total charge, in dollars (SE) 27 915 (65.8) 28 843 (148.1) 27 700 (73.4)
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Table 2
Coefficient Estimates of Costs of Stroke Hospitalizations for Patients Aged 65 Years or Older, 2010 Medicare 
Provider Analysis and Review File Data
Variables or SubGroups Total Sample
Higher Cost Associated with AF from 
Subgroup Analysis
CoEfficient a Costa
Atrial Fibrillation 2711 ---
Age 65–74 10 163 3159
75–84 5567 2610
85 + Referent 2197
Sex Male 1774 2481
Female Referent 2865
Race Black −446 2829
Non-black Referent 2724
Length of Stay 1–6 −31 529 663
7–13 −13 121 5145
14–29 Referent 5888
Initial Versus Readmission Initial admission 12 354 2844
Readmission Referent 1735
Primary Versus Non-Primary Stroke Primary stroke −876 2778
Non-primary stroke Referent 2521
Intracerebral Hemorrhage (ICH) Versus Infarction ICH 10 101 1364
Non-ICH stroke Referent 2757
Charlson Comorbidity Indexb 548 ---
Note: All p≤0.001, except the higher cost associated with AF for ICH patients with a p-value of 0.17
a
Coefficient and costs are in dollars,
b
Charlson Index measures the likelihood of death or serious disability in the subsequent year by diagnosis codes for up to 18 different diseases
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